Lipella PharmaceuticalsLIPO
LIPO
About: Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.
Employees: 7
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
4% more capital invested
Capital invested by funds: $39.7K [Q3] → $41.4K (+$1.7K) [Q4]
0.05% more ownership
Funds ownership: 1.06% [Q3] → 1.11% (+0.05%) [Q4]
40% less funds holding
Funds holding: 5 [Q3] → 3 (-2) [Q4]
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Research analyst outlook
We haven’t received any recent analyst ratings for LIPO.
Financial journalist opinion
Based on 5 articles about LIPO published over the past 30 days
Neutral
GlobeNewsWire
5 days ago
Spartan Capital Securities, LLC Announces Key February Transactions
New York, NY, March 07, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is pleased to announce a series of strategic transactions completed in February 2025, reinforcing its position as a trusted financial partner for companies across diverse industries.
Neutral
GlobeNewsWire
1 week ago
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $3,788,000 Private Placement
New York, NY, March 04, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of a $3,788,000 private placement for Lipella Pharmaceuticals Inc. (Nasdaq: LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in this private offering.
Positive
Benzinga
4 weeks ago
Nano Cap Lipella Pharmaceuticals Stock Jumps On Positive Trial Data In Patients With Sore Mouth Membranes
On Tuesday, Lipella Pharmaceuticals Inc. LIPO shared topline an analysis of its Phase 2a dose-ranging trial of LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus (OLP).
Neutral
MCAP MediaWire
4 weeks ago
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
PITTSBURGH, Feb. 11, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc.
Neutral
GlobeNewsWire
4 weeks ago
Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in the Treatment of Oral Lichen Planus
LP-310 Treatment Demonstrates Clinically Meaningful Reductions in Pain, Ulceration, and Inflammation Across All Key Metrics Findings Highlight Favorable Safety Profile and Tolerability of Twice-Daily Oral Rinse Multicenter Phase 2a Trial Advancing to Higher Treatment Dose with Recruitment Expected to Conclude the First Half of 2025 Lipella Leadership to Present Findings at BIO CEO & Investor Conference on Tuesday, February 11, 2025, at 2:30 p.m. EST PITTSBURGH, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella,” “our,” “us,” or the “Company”), a clinical-stage biotechnology company addressing serious diseases with significant unmet needs, today shared topline analysis of its Phase 2a multicenter dose-ranging trial examining LP-310, a liposomal-tacrolimus oral rinse formulation of LP-10 being developed to treat oral lichen planus (“OLP”).
Neutral
GlobeNewsWire
1 month ago
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for an Expanded Access Program (EAP) for LP-310, an oral rinse formulation designed to treat oral lichen planus (OLP). LP-310 is an innovative, localized therapy formulated to provide targeted relief for OLP patients while minimizing systemic exposure.
Neutral
MCAP MediaWire
1 month ago
Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus
PITTSBURGH, February 6, 2025 – PRISM MediaWire – Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced that the U.S.
Neutral
GlobeNewsWire
2 months ago
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $875,500 Private Placement
New York, NY, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a premier investment banking firm, is pleased to announce the successful completion of two private placements for Lipella Pharmaceuticals Inc. (Nasdaq: LIPO). Spartan Capital Securities, LLC acted as the sole placement agent in these private offerings of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc., raising an aggregate total of $875,500 through the transactions.
Neutral
GlobeNewsWire
2 months ago
Spartan Capital Securities, LLC Caps Off a Remarkable Year with Key December Transactions
New York, NY, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a full-service investment banking firm, is proud to announce a series of notable transactions completed in December 2024, further solidifying its reputation as a trusted partner for fast-growing companies across diverse industries.
Neutral
GlobeNewsWire
2 months ago
Spartan Capital Securities, LLC Serves as Sole Placement Agent in Lipella Pharmaceuticals Inc.'s $1.72 Million Private Placement
New York, NY, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities LLC, a premier investment banking firm, is pleased to announce the successful completion of a private placement for Lipella Pharmaceuticals Inc.'s (Nasdaq: LIPO) Spartan Capital Securities, LLC acted as the sole placement agent in the private offer and sale of up to 6,000,000 of Series B non-voting convertible preferred stock of Lipella Pharmaceuticals Inc. Lipella Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, successfully raised $1,722,000 through this private placement.
Charts implemented using Lightweight Charts™